ARRY-502 is an orally active, potent and selective CRTh2 antagonist. ARRY-502 blocks PGD2-mediated Th2 inflammation (e.g., eosinophil activation, airway hyperresponsiveness). ARRY-502 is promising for research of Th2-related asthma.
Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Prostaglandin Receptor
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye